Ling Zhang
About Ling Zhang
Ling Zhang is a Senior Scientist at Bristol Myers Squibb with extensive experience in biophysics, pharmacology, and biochemistry. She has held various scientific roles at Kriya Therapeutics, LakePharma, Inc., UCSF, and University of Pittsburgh and Carnegie Mellon University.
Current Title and Role
Ling Zhang currently holds the position of Senior Scientist at Bristol Myers Squibb in Redwood City, California, United States. In this role, Zhang contributes significantly to various portfolio program meetings by providing data essential for the development of multiple modalities. These modalities include Antibody-Drug Conjugates (ADC), T cell engagers, CAR-T therapies, and bispecific antibodies.
Previous Professional Experience
Ling Zhang has extensive experience in the biotechnology and pharmaceutical industries. Zhang served as a Senior Scientist at Kriya Therapeutics for 2 months in 2021 in Redwood City, California. Prior to that, Zhang worked at LakePharma, Inc. as Scientist II for three years from 2018 to 2021 in San Carlos. Zhang also held roles at UCSF, initially as a Postdoc and Associate Specialist from 2013 to 2016, and later as a Staff Research Associate for 11 months in 2017. Between 2008 and 2013, Zhang was a Postdoc at the University of Pittsburgh and Carnigie Mellon University.
Education and Academic Background
Ling Zhang has an impressive academic background with multiple advanced degrees. Zhang earned a Ph.D. in Biophysics from Tsinghua University. Before that, Zhang obtained a Master's degree in Pharmacology from Peking Union Medical College. Additionally, Zhang holds a Bachelor's degree in Biochemistry from Jilin University. This strong educational foundation has provided Zhang with a comprehensive understanding of various scientific principles and methodologies.
Technical Expertise and Research Contributions
Ling Zhang possesses state-of-the-art experience in antibody discovery and screening using hybridoma and phage display platforms. Zhang also has expertise in CRISPR/Cas9 based cell screening techniques. Additionally, Zhang led significant advancements in immunization technology involving mRNA and lipid nanoparticles (LNP). Furthermore, Zhang enhanced immune responses by experimenting with various adjuvant combinations. These technical skills showcase Zhang's versatility and proficiency in multiple cutting-edge research areas.